Delandistrogene moxeparvovec

莫哌德兰基

Report date: 2024/05/17 12:02:53

Base Information

Drug NameDelandistrogene moxeparvovec
Drug Alias NameAAVrh74.MHCK7.micro dystrophinAAVrh74.MHCK7.micro-Dystrophin - Nationwide Children's HospitalmicrodystrophinDelandistrogen MoxeparvovecDelandistrogene moxeparvovec-rokl +[13] 
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAVrh74 vector
Mechanisms of ActionDystrophin gene transference
TargetsDystrophin
Therapy Area/IndicationsMuscular Dystrophy, Duchenne
Global Approved IndicationsMuscular Dystrophy, Duchenne
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2023/06/22
Country/TerritoryBelgiumUnited StatesTaiwan +[10] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesNationwide Children'S Hospital
China Registration ClassN/A

Develop Information

Active CompaniesSarepta Therapeutics IncF. Hoffmann-La Roche Ltd
Inactive CompaniesRoche Registration Gmbh
Active IndicationsMuscular Dystrophy, Duchenne
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A